Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Increased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 10.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,133 shares of the company’s stock after purchasing an additional 295 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Protagonist Therapeutics were worth $121,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of PTGX. Pacer Advisors Inc. lifted its stake in Protagonist Therapeutics by 405,061.2% in the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock valued at $78,034,000 after acquiring an additional 1,733,662 shares during the last quarter. State Street Corp increased its stake in shares of Protagonist Therapeutics by 52.9% during the 3rd quarter. State Street Corp now owns 3,183,542 shares of the company’s stock worth $143,259,000 after purchasing an additional 1,101,218 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Protagonist Therapeutics by 2,135.6% during the 2nd quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock valued at $33,205,000 after purchasing an additional 915,418 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Protagonist Therapeutics by 3,099.4% in the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock valued at $14,437,000 after purchasing an additional 310,804 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Protagonist Therapeutics in the second quarter worth $5,467,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $39.12 on Friday. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $48.89. The firm has a market capitalization of $2.33 billion, a P/E ratio of 14.71 and a beta of 2.23. The company has a 50-day simple moving average of $39.90 and a 200-day simple moving average of $41.83.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $4.68 million during the quarter, compared to the consensus estimate of $4.50 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. As a group, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on PTGX. StockNews.com cut Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. The Goldman Sachs Group initiated coverage on Protagonist Therapeutics in a report on Friday, December 6th. They issued a “neutral” rating and a $47.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, December 10th. Finally, BMO Capital Markets initiated coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $62.00 price objective for the company. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.78.

Insiders Place Their Bets

In related news, insider Suneel Gupta sold 103,437 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the completion of the transaction, the insider now owns 256,174 shares in the company, valued at $11,794,250.96. This trade represents a 28.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Arturo Md Molina sold 26,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $44.70, for a total transaction of $1,162,200.00. Following the completion of the sale, the insider now owns 46,444 shares in the company, valued at $2,076,046.80. This represents a 35.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 209,863 shares of company stock worth $9,689,847 over the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.